Free Trial
NASDAQ:STOK

Stoke Therapeutics (STOK) Stock Price, News & Analysis

Stoke Therapeutics logo
$12.36
-0.14 (-1.12%)
(As of 10/31/2024 ET)

About Stoke Therapeutics Stock (NASDAQ:STOK)

Key Stats

Today's Range
$12.26
$12.44
50-Day Range
$11.40
$15.92
52-Week Range
$3.46
$17.58
Volume
539,249 shs
Average Volume
766,677 shs
Market Capitalization
$644.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.83
Consensus Rating
Buy

Company Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stoke Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
77th Percentile Overall Score

STOK MarketRank™: 

Stoke Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 275th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Stoke Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Stoke Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.10) to ($2.59) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Stoke Therapeutics is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Stoke Therapeutics is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Stoke Therapeutics has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Stoke Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    13.03% of the outstanding shares of Stoke Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Stoke Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Stoke Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving.
  • Dividend Yield

    Stoke Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Stoke Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.03% of the outstanding shares of Stoke Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Stoke Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Stoke Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving.
  • News Sentiment

    Stoke Therapeutics has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Stoke Therapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    Only 4 people have searched for STOK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,221,875.00 in company stock.

  • Percentage Held by Insiders

    11.30% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Stoke Therapeutics' insider trading history.
Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Stock News Headlines

Stoke Therapeutics assumed with an Outperform at Leerink
Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
See More Headlines

STOK Stock Analysis - Frequently Asked Questions

Stoke Therapeutics' stock was trading at $5.26 at the beginning of 2024. Since then, STOK stock has increased by 135.0% and is now trading at $12.36.
View the best growth stocks for 2024 here
.

Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.11. The company had revenue of $4.83 million for the quarter, compared to analysts' expectations of $3.33 million. Stoke Therapeutics had a negative trailing twelve-month return on equity of 57.89% and a negative net margin of 683.35%.

Stoke Therapeutics (STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Stoke Therapeutics' top institutional shareholders include Skorpios Trust (16.92%), Assenagon Asset Management S.A. (2.49%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Skorpios Trust, Stephen J Tulipano, Jonathan Allan, Barry Ticho and Huw M Nash.
View institutional ownership trends
.

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA).

Company Calendar

Last Earnings
8/07/2024
Today
10/31/2024
Next Earnings (Estimated)
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:STOK
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.83
High Stock Price Target
$35.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+68.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-104,700,000.00
Net Margins
-683.35%
Pretax Margin
-683.35%

Debt

Sales & Book Value

Annual Sales
$15.16 million
Book Value
$3.57 per share

Miscellaneous

Free Float
46,699,000
Market Cap
$645.26 million
Optionable
Optionable
Beta
0.97
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:STOK) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners